|
1
|
Husheem M, Nyman JK, Vääräniemi J,
Vaananen HK and Hentunen TA: Characterization of circulating human
osteoclast progenitors: development of in vitro resorption assay.
Calcif Tissue Int. 76:222–230. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Boyle WJ, Simonet WS and Lacey DL:
Osteoclast differentiation and activation. Nature. 423:337–342.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Väänänen HK and Laitala-Leinonen T:
Osteoclast lineage and function. Arch Biochem Biophys. 473:132–138.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Teitelbaum SL: Bone resorption by
osteoclasts. Science. 289:1504–1508. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Väänänen HK, Zhao H, Mulari M and Halleen
JM: The cell biology of osteoclast function. J Cell Sci.
113:377–381. 2000.PubMed/NCBI
|
|
6
|
Jansen ID, Vermeer JA, Bloemen V, Stap J
and Everts V: Osteoclast fusion and fission. Calcif Tissue Int.
90:515–522. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yasuda H, Shima N, Nakagawa N, et al:
Osteoclast differentiation factor is a ligand for
osteoprotegerin/osteoclastogenesis-inhibitory factor and is
identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:3597–3602.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lacey DL, Timms E, Tan HL, et al:
Osteoprotegerin ligand is a cytokine that regulates osteoclast
differentiation and activation. Cell. 93:165–176. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hofbauer LC, Kühne CA and Viereck V: The
OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet
Neuronal Interact. 4:268–275. 2004.PubMed/NCBI
|
|
10
|
Khosla S: Minireview: the OPG/RANKL/RANK
system. Endocrinology. 142:5050–5055. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Song R, Gu J, Liu X, et al: Inhibition of
osteoclast bone resorption activity through osteoprotegerin-induced
damage of the sealing zone. Int J Mol Med. 34:856–862.
2014.PubMed/NCBI
|
|
12
|
Singh PP, van der Kraan AG, Xu J,
Gillespie MT and Quinn JM: Membrane-bound receptor activator of
NFκB ligand (RANKL) activity displayed by osteoblasts is
differentially regulated by osteolytic factors. Biochem Biophys Res
Commun. 422:48–53. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang J, Chen TY, Qin S, Duan Y and Wang G:
Inhibitory effect of metformin on bone metastasis of cancer via
OPG/RANKL/RANK system. Med Hypotheses. 81:805–806. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shiotani A, Takami M, Itoh K, Shibasaki Y
and Sasaki T: Regulation of osteoclast differentiation and function
by receptor activator of NFκB ligand and osteoprotegerin. Anat Rec.
268:137–146. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Z, Xu J, EL and Wang D: Ultrasound
enhances the healing of orthodontically induced root resorption in
rats. Angle Orthod. 82:48–55. 2012. View Article : Google Scholar
|
|
16
|
Fu YX, Gu JH, Zhang YR, Tong XS, Zhao HY,
Yuan Y, Liu XZ, Bian JC and Liu ZP: Influence of osteoprotegerin on
differentiation, activation, and apoptosis of Gaoyou duck embryo
osteoclasts in vitro. Poult Sci. 92:1613–1620. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li CH, Zhao JX, Sun L, Yao ZQ, Deng XL,
Liu R and Liu XY: AG490 inhibits NFATc1 expression and STAT3
activation during RANKL induced osteoclastogenesis. Biochem Biophys
Res Commun. 435:533–539. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Robertson Remen KM, Gustafsson JÅ and
Andersson G: The liver X receptor promotes macrophage
differentiation and suppresses osteoclast formation in mouse
RAW264.7 promyelocytic leukemia cells exposed to bacterial
lipopolysaccharide. Biochem Biophys Res Commun. 430:375–380. 2013.
View Article : Google Scholar
|
|
19
|
Sinningen K, Rauner M, Goettsch C,
Al-Fakhri N, Schoppet M and Hofbauer LC: Monocytic expression of
osteoclast-associated receptor (OSCAR) is induced in
atherosclerotic mice and regulated by oxidized low-density
lipoprotein in vitro. Biochem Biophys Res Commun. 437:314–318.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Song RL, Liu XZ, Zhu JQ, et al: New roles
of filopodia and podosomes in the differentiation and fusion
process of osteoclasts. Genet Mol Res. 13:4776–4787. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Etienne-Manneville S and Hall A: Rho
GTPases in cell biology. Nature. 420:629–635. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Coxon FP and Rogers MJ: The role of
prenylated small GTP-binding proteins in the regulation of
osteoclast function. Calcif Tissue Int. 72:80–84. 2003. View Article : Google Scholar
|
|
23
|
Vega FM and Ridley AJ: SnapShot: Rho
family GTPases. Cell. 129:14302007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakamura H, Hirata A, Tsuji T and Yamamoto
T: Role of osteoclast extracellular signal-regulated kinase (ERK)
in cell survival and maintenance of cell polarity. J Bone Miner
Res. 18:1198–1205. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang N, Robaye B, Agrawal A, Skerry TM,
Boeynaems JM and Gartland A: Reduced bone turnover in mice lacking
the P2Y(13) receptor of ADP. Mol Endocrinol. 26:142–152. 2012.
View Article : Google Scholar
|
|
26
|
Fukuda A, Hikita A, Wakeyama H, Akiyama T,
Oda H, Nakamura K and Tanaka S: Regulation of osteoclast apoptosis
and motility by small GTPase binding protein Rac1. J Bone Miner
Res. 20:2245–2253. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shepelev MV, Chernoff J and Korobko IV:
Rho family GTPase Chp/RhoV induces PC12 apoptotic cell death via
JNK activation. Small GTPases. 2:17–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chamoux E, Houde N, L’Eriger K and Roux S:
Osteoprotegerin decreases human osteoclast apoptosis by inhibiting
the TRAIL pathway. J Cell Physiol. 216:536–542. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schindler AE: Climacteric symptoms and
hormones. Gynecol Endocrinol. 22:151–154. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Blair HC, Robinson LJ and Zaidi M:
Osteoclast signalling pathways. Biochem Biophys Res Commun.
328:728–738. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Syed F and Khosla S: Mechanisms of sex
steroid effects on bone. Biochem Biophys Res Commun. 328:688–696.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stolberg M: From the ‘climacteric disease’
to the ‘male climacteric’ The historical origins of a modern
concept. Maturitas. 58:111–116. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rollenhagen C and Asin SN: Enhanced HIV-1
replication in ex vivo ectocervical tissues from post-menopausal
women correlates with increased inflammatory responses. Mucosal
Immunol. 4:671–681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Breuil V, Ticchioni M, Testa J, et al:
Immune changes in post-menopausal osteoporosis: the Immunos study.
Osteoporos Int. 21:805–814. 2010. View Article : Google Scholar
|
|
35
|
Ambrogini E, Toraldo G and Marcocci C:
Post-menopausal osteoporosis: is it an autoimmune disease? J
Endocrinol Invest. 28:43–47. 2005.
|
|
36
|
Li F, Jiang Q, Shi KJ, Luo H, Yang Y and
Xu CM: RhoA modulates functional and physical interaction between
ROCK1 and Erk1/2 in selenite-induced apoptosis of leukaemia cells.
Cell Death Dis. 4:e7082013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ullah I, Lee HY, Kim MJ, Shah SA, Badshah
H, Kim TH, Chung HJ, Yang BC and Kim MO: Rho GTPase activating
protein 15 (arhGAP15) siRNA effect apoptosis-induced by ethanol in
bovine fibroblast cells. Pak J Pharm Sci. 26:605–610.
2013.PubMed/NCBI
|
